Becker Muscular Dystrophy (BMD) Clinical Trials

Becker Muscular Dystrophy results from mutations in the dystrophin gene on the X chromosome that produce an internally deleted or abnormal but partially functional dystrophin protein. In contrast to DMD mutations causing complete dystrophin absence or non-functional protein, BMD mutations preserve the reading frame and allow production of shorter but partially active dystrophin. The amount of residual dystrophin function correlates with disease severity and age of onset.

The most common symptoms of Becker Muscular Dystrophy include Progressive muscle weakness starting in hip and thigh muscles, Calf hypertrophy and muscle wasting in other areas, Waddling gait and difficulty climbing stairs, Myoglobinuria causing dark urine after intense activity, Cramps and muscle pain, among others. Approximately 1 to 5 per 100,000 males; about 1/3 to 1/2 the prevalence of Duchenne Muscular Dystrophy. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Becker Muscular Dystrophy from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Becker Muscular Dystrophy research is advancing through multiple strategies to restore or enhance dystrophin function. Exon-skipping antisense oligonucleotides, stop codon readthrough therapies, and gene therapy approaches all work toward the goal of restoring functional dystrophin.

As of October 21, 2026, no current FDA drug label names Becker Muscular Dystrophy as a condition the drug treats.

Becker Muscular Dystrophy is caused by variants in the DMD gene. Becker results from DMD variants that leave partially functional dystrophin (usually in-frame deletions); Duchenne from variants that abolish it. Female carriers can have cardiomyopathy.

It is X-linked, so it mainly affects boys, and a mother who carries the variant has a 1 in 2 chance of passing it to each son. Approximately 1 to 5 per 100,000 males; about 1/3 to 1/2 the prevalence of Duchenne Muscular Dystrophy. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Becker Muscular Dystrophy looks at the DMD gene. Becker results from DMD variants that leave partially functional dystrophin (usually in-frame deletions); Duchenne from variants that abolish it. Female carriers can have cardiomyopathy.

It is X-linked, so it mainly affects boys, and a mother who carries the variant has a 1 in 2 chance of passing it to each son.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Becker Muscular Dystrophy clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Becker Muscular Dystrophy clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.